Mount Sinai School of Medicine and Bionostra Group collaborate to develop avian flu vaccine

The Mount Sinai School of Medicine announced today it will collaborate with the prestigious Bionostra Group of Spain to develop an avian flu vaccine. The vaccine will protect against the lethal infection of the H5N1 virus.

Founded in 2000, Bionostra - - in collaboration with members of the Consejo Superior de Investigaciones Científicas (CSIC) which is the Spanish High Council of Scientific Research - - has developed a new technology based on virus-like-particles to provide a new generation of vaccines for human and animal health. These novel technology, will offer researchers at Mount Sinai School of Medicine a great jumping off point in the creation of the vaccine.

"We are enthusiastic with this promising collaboration between Bionostra and the Mount Sinai School of Medicine which is renowned for its prestigious scientific research," said Juan Carlos del Castillo Tamayo, CEO of Bionostra. "This is the first step for a revolutionary new generation of vaccines against the influenza virus."


Mount Sinai School of Medicine has been at the forefront in the study of the influenza virus. The reconstruction of the 1918 influenza virus, a recent scientific breakthrough, was made possible by a technique developed and patented by Mount Sinai School of Medicine researchers. The virus was reconstructed using reverse genetics, a technique developed by Adolfo Garcia-Sastre, PhD, Professor of Microbiology and Peter Palese, PhD, Professor and Chairman of Microbiology at Mount Sinai School of Medicine. The collaboration with Bionostra will offer Mount Sinai's researchers an even greater understanding of the pathology of the H5N1 virus and will result in the development of a novel vaccine that combats this burgeoning pandemic.

Mount Sinai School of Medicine
Located in Manhattan, Mount Sinai School of Medicine is internationally recognized for ground-breaking clinical and basic-science research, and innovative approaches to medical education. Through the Mount Sinai Graduate School of Biological Sciences, Mount Sinai trains biomedical researchers with an emphasis on the rapid translation of discoveries of basic research into new techniques for fighting disease. One indication of Mount Sinai's leadership in scientific investigation is its receipt during fiscal year 2004 of $153.2 million. Mount Sinai now ranks 25th among the nation's medical schools in receipt of research support from NIH. Mount Sinai School of Medicine also is known for unique educational programs such as the Humanities in Medicine program, which creates opportunities for liberal arts students to pursue medical school, and instructional innovations like The Morchand Center, the nation's largest program teaching students and physicians with "standardized patients" to become not only highly skilled, but compassionate caregivers. Long dedicated to improving its community, the School extends its boundaries to work with East Harlem and surrounding communities to provide access to health care and educational programs to at risk populations.

Last reviewed: By John M. Grohol, Psy.D. on 30 Apr 2016
    Published on All rights reserved.